2019-02-15 Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
2019-02-14 Bayer’s darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer
2019-02-05 Bayer to showcase new data from its growing cancer portfolio at 2019 ASCO GU Cancers Symposium
2019-01-31 Bayer and Kyoto University form research alliance to discover new treatment approaches against lung diseases